Amgen Welcomes David W. Gibbs to Board of Directors to Enhance Leadership Team

Amgen Appoints David W. Gibbs to Board of Directors

In an exciting development for the biopharmaceutical industry, Amgen (NASDAQ: AMGN) has appointed David W. Gibbs to its Board of Directors. This decision, effective immediately, reflects the company's ongoing effort to strengthen its leadership and strategic direction.

Gibbs brings a wealth of experience to Amgen, having recently concluded a significant tenure as the President and CEO of Yum! Brands, the global company behind well-known fast-food chains like Taco Bell and Kentucky Fried Chicken. During his five-year term as CEO from 2020 to 2025, he spearheaded the company’s digital transformation and expanded its reach to almost 61,000 locations across the globe.

A Leader with Proven Expertise in Consumer Brands

David Gibbs's career is marked by a series of high-profile leadership roles within Yum! Brands, which established him as a competent leader in the industry.

Beyond his role at Yum! Brands, Gibbs has extensive experience in board governance. Since 2021, he has been serving on the Board of Directors for Under Armour, where he chairs the Human Capital and Compensation Committee. He also recently joined the Board of PepsiCo in 2026, contributing his insights on the Audit Committee. His extensive background in managing consumer relationships and company performance will be invaluable at Amgen, especially as the company seeks to enhance its engagement with patients and healthcare providers.

Comments from Leadership

Amgen's Chairman and CEO, Robert A. Bradway, expressed enthusiasm over Gibbs' appointment, stating, “We are excited to welcome David to Amgen's Board. With his proven record in leading some of the world's most recognized consumer brands, we look forward to leveraging his expertise as we innovate and bring new therapies to patients around the globe.”

Educational Background

Gibbs holds a Bachelor’s degree in Mathematical Science from Johns Hopkins University and an MBA from Duke University’s Fuqua School of Business. This solid educational foundation complements his extensive industry experience, making him a strong asset to the Amgen Board.

Amgen’s Mission and Vision

For over 45 years, Amgen has been a pioneer in biotechnology, delivering innovative therapies for serious diseases. Originating in Thousand Oaks, California, Amgen continues to harness cutting-edge technology and biological research to push boundaries in medicine. With a diverse portfolio, Amgen aims to address critical health challenges ranging from cancer to cardiovascular diseases and obesity.

In conclusion, David W. Gibbs' appointment to Amgen's Board is not just a strategic move but a commitment to fostering innovation in patient care. As the company continues to advance its mission, Gibbs's insight into consumer engagement will play a vital role in shaping its future endeavors. The Board now consists of 13 members, with 12 being independent, as Amgen embarks on new horizons in biotechnology and pharmaceuticals.